Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Organization

Virginia Commonwealth University Health System

7 abstracts

Abstract
A multicenter phase II study of cabozantinib + nivolumab for patients (pts) with advanced angiosarcoma (AS) previously treated with a taxane (Alliance A091902).
Org: Duke University Medical Center, Mayo Clinic, Vanderbilt University Medical Center, Virginia Commonwealth University Health System, Duke Cancer Institute,
Abstract
Effectiveness of a cardiovascular health EHR application for cancer survivors in community oncology practice: Results from WF-1804CD.
Org: University of Kansas School of Medicine, Wake Forest School of Medicine, Mercy Hospital Springfield, Washington University School of Medicine Saint Louis, Washington University in St. Louis School of Medicine,
Abstract
EROS: Engendering reproductive health within oncologic survivorship—ECOG-ACRIN E1Q11 paradoxical provision of reproductive health.
Org: Cook County Hospital, Dana-Farber Cancer Institute, ECOG-ACRIN Biostatistics Center, Lewis Cancer & Research Pavilion at St. Joseph's Candler/GA NCORP, SHCC MU-NCORP,
Abstract
If you build it, they will come: Success of the EROS (Engendering Reproductive Health Within Oncologic Survivorship)—ECOG-ACRIN E1Q11 in recruitment of minority patients.
Org: Cook County Hospital, Dana-Farber Cancer Institute, ECOG-ACRIN Biostatistics Center, Lewis Cancer & Research Pavilion at St. Joseph's Candler/GA NCORP, SHCC MU-NCORP,
Abstract
Alliance A091902: A multicenter randomized phase II trial of paclitaxel (P) with or without nivolumab (N) in patients (pts) with advanced angiosarcoma (AS).
Org: Duke Cancer Institute, Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC, Durham, NC, Mayo Clinic, Rochester, MN,
Abstract
Tumor-informed circulating tumor DNA (TI-ctDNA) based molecular residual disease (MRD) detection and relapse risk for patients with stage II-IV melanoma in surgical remission: A single center experience.
Org: Virginia Commonwealth University Health System, Virginia Commonwealth University School of Medicine,
Abstract
Real world utilization and disparities in outcome in the use of novel anti-androgen agents for metastatic prostate cancer.
Org: Virginia Commonwealth University Health System, Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan, Virginia Commonwealth University School of Medicine, VCU School of Medicine, Virginia Commonwealth University Medical Center,